Zhang Z, Zhai ZG, Liang LR, Liu FF, Yang YH, Wang C (March 2014). "Lower dosage of recombinant tissue-type plasminogen activator (rt-PA) in the treatment of acute pulmonary embolism: a systematic review and meta-analysis". Thrombosis Research. 133 (3): 357–63. doi:10.1016/j.thromres.2013.12.026. PMID24412030.
Hilleman D, Campbell J (October 2011). "Efficacy, safety, and cost of thrombolytic agents for the management of dysfunctional hemodialysis catheters: a systematic review". Pharmacotherapy. 31 (10): 1031–40. doi:10.1592/phco.31.10.1031. PMID21950645. S2CID2092899.
Parker S, Ali Y (October 2015). "Changing contraindications for t-PA in acute stroke: review of 20 years since NINDS". Current Cardiology Reports. 17 (10): 81. doi:10.1007/s11886-015-0633-5. PMID26277361. S2CID26427160.
Campbell BC, Meretoja A, Donnan GA, Davis SM (August 2015). "Twenty-Year History of the Evolution of Stroke Thrombolysis With Intravenous Alteplase to Reduce Long-Term Disability". Stroke. 46 (8): 2341–6. doi:10.1161/STROKEAHA.114.007564. PMID26152294. S2CID207614164.
Sun M (3 July 1987). "FDA Puts New Heart Drug on Hold: A surprise decision by the FDA to withhold approval of TPA, a potent clot-dissolving drug, highlights a scientific debate among cardiologists". Science. 237 (4810): 16–18. doi:10.1126/science.3110948. PMID3110948.
World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
World Health Organization (2019). Executive summary: the selection and use of essential medicines 2019: report of the 22nd WHO Expert Committee on the selection and use of essential medicines. Geneva: World Health Organization. hdl:10665/325773. WHO/MVP/EMP/IAU/2019.05. License: CC BY-NC-SA 3.0 IGO.
Jilani TN, Siddiqui AH (April 2020). "Tissue Plasminogen Activator". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID29939694. Archived from the original on 29 January 2021. Retrieved 10 November 2020.
Reed M, Kerndt CC, Nicolas D (2020). "Alteplase". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID29763152. Archived from the original on 29 January 2021. Retrieved 30 October 2020.
Zhang Z, Zhai ZG, Liang LR, Liu FF, Yang YH, Wang C (March 2014). "Lower dosage of recombinant tissue-type plasminogen activator (rt-PA) in the treatment of acute pulmonary embolism: a systematic review and meta-analysis". Thrombosis Research. 133 (3): 357–63. doi:10.1016/j.thromres.2013.12.026. PMID24412030.
Hilleman D, Campbell J (October 2011). "Efficacy, safety, and cost of thrombolytic agents for the management of dysfunctional hemodialysis catheters: a systematic review". Pharmacotherapy. 31 (10): 1031–40. doi:10.1592/phco.31.10.1031. PMID21950645. S2CID2092899.
Parker S, Ali Y (October 2015). "Changing contraindications for t-PA in acute stroke: review of 20 years since NINDS". Current Cardiology Reports. 17 (10): 81. doi:10.1007/s11886-015-0633-5. PMID26277361. S2CID26427160.
Campbell BC, Meretoja A, Donnan GA, Davis SM (August 2015). "Twenty-Year History of the Evolution of Stroke Thrombolysis With Intravenous Alteplase to Reduce Long-Term Disability". Stroke. 46 (8): 2341–6. doi:10.1161/STROKEAHA.114.007564. PMID26152294. S2CID207614164.
Sun M (3 July 1987). "FDA Puts New Heart Drug on Hold: A surprise decision by the FDA to withhold approval of TPA, a potent clot-dissolving drug, highlights a scientific debate among cardiologists". Science. 237 (4810): 16–18. doi:10.1126/science.3110948. PMID3110948.
Jilani TN, Siddiqui AH (April 2020). "Tissue Plasminogen Activator". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID29939694. Archived from the original on 29 January 2021. Retrieved 10 November 2020.
Reed M, Kerndt CC, Nicolas D (2020). "Alteplase". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID29763152. Archived from the original on 29 January 2021. Retrieved 30 October 2020.
Hilleman D, Campbell J (October 2011). "Efficacy, safety, and cost of thrombolytic agents for the management of dysfunctional hemodialysis catheters: a systematic review". Pharmacotherapy. 31 (10): 1031–40. doi:10.1592/phco.31.10.1031. PMID21950645. S2CID2092899.
Parker S, Ali Y (October 2015). "Changing contraindications for t-PA in acute stroke: review of 20 years since NINDS". Current Cardiology Reports. 17 (10): 81. doi:10.1007/s11886-015-0633-5. PMID26277361. S2CID26427160.
Campbell BC, Meretoja A, Donnan GA, Davis SM (August 2015). "Twenty-Year History of the Evolution of Stroke Thrombolysis With Intravenous Alteplase to Reduce Long-Term Disability". Stroke. 46 (8): 2341–6. doi:10.1161/STROKEAHA.114.007564. PMID26152294. S2CID207614164.
Jilani TN, Siddiqui AH (April 2020). "Tissue Plasminogen Activator". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID29939694. Archived from the original on 29 January 2021. Retrieved 10 November 2020.
Reed M, Kerndt CC, Nicolas D (2020). "Alteplase". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID29763152. Archived from the original on 29 January 2021. Retrieved 30 October 2020.